• Erasca reported updated preliminary Phase 1 AURORAS-1 data for pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors.
• In second-line or later KRAS G12X pancreatic cancer, uORR at 8 weeks was 57% (N=7) at the 32 mg once-daily expansion dose.
• Safety profile remained broadly consistent with prior disclosure; no dose-limiting toxicities were reported, no treatment discontinuations due to TRAEs.
• One pneumonitis case progressed to a fatal outcome following withdrawal of supportive care.
• Development plans include a potentially registration-enabling NSCLC trial in 1H 2027, a Phase 3 PDAC first-line trial in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-302045), on July 13, 2026, and is solely responsible for the information contained therein.